CD4 T-helper differentiation

Category: immune_innate

Overview

Naive CD4+ T cells polarize into distinct effector lineages based on cytokine environment + master transcription factors. Lineage signatures: (1) Th1 — IL-12 + IFN-γ; T-bet (TBX21); cytokines IFN-γ + TNF-α + IL-2; intracellular pathogens + macrophage activation. (2) Th2 — IL-4; GATA3; cytokines IL-4 + IL-5 + IL-13; helminth defense + allergic disease (cross-link asthma th2 eosinophil inflammation). (3) Th17 — TGF-β + IL-6 + IL-23; RORγt; cytokines IL-17A/F + IL-22; extracellular bacteria + fungi at mucosa; autoimmune (psoriasis, IBD, axial spondylitis). (4) iTreg — TGF-β + IL-2; FoxP3; cytokines IL-10 + TGF-β; immune tolerance + suppressing other lineages. (5) Tfh — IL-6 + IL-21; Bcl-6; CXCR5; B-cell germinal center help. Plasticity: lineages are not fully terminal — Th17 ↔ iTreg interconversion (shared TGF-β requirement; IL-6 sets the balance); ex-Th17 → Th1-like in chronic inflammation. Metabolic profile: effector Th1/Th17 prefer glycolysis (mTORC1-dependent); Treg prefer fatty-acid oxidation (AMPK-dependent — cross-link ampk signaling + mtor signaling). Disease relevance: Th1 — MS, T1D; Th2 — asthma, allergy; Th17 — psoriasis, IBD, AS; Treg deficiency — IPEX (FoxP3 LOF). Therapeutic landscape: calcineurin inhibitors (block IL-2 → all lineages); mTOR inhibitors (rapamycin — expands Treg, suppresses Teff); methotrexate; JAK inhibitors (tofacitinib, baricitinib — IL-6/IFN/IL-12/23 downstream); cytokine-specific biologics: anti-IL-17 (secukinumab, ixekizumab), anti-IL-23 (ustekinumab, risankizumab); anti-IL-4Rα (dupilumab — Th2 blockade); CTLA-4-Ig (abatacept). Cross-links: kynurenine tryptophan pathway (IDO → Treg induction), asthma th2 eosinophil inflammation, calcineurin nfat t cell activation.

Organ Systems

Pathway Steps

  1. naive CD4+ T cell + TCR + IL-12 → Th1 polarization (T-bet+) — via STAT4-IL-12 → T-bet → IFN-γ feed-forward. Naive CD4 T cells differentiate by the cytokines present at activation. IL-12 (from dendritic cells sensing intracellular microbes) with IFN-γ drives Th1 via the master factor T-bet. Th1 cells make IFN-γ to activate macrophages against intracellular pathogens — and when dysregulated drive organ-specific autoimmunity.
  2. naive CD4+ + IL-4 → Th2 polarization (GATA3+) — via STAT6-IL-4 → GATA3 → IL-4/5/13 production. IL-4 polarizes naive CD4 cells to Th2 via the master regulator GATA-3 in a self-amplifying, STAT6-dependent loop. Th2 cells produce IL-4/IL-5/IL-13 to drive antibody and eosinophil responses against helminths — and, when misdirected, allergy and asthma.
  3. naive CD4+ + TGF-β + IL-6 + IL-23 → Th17 polarization (RORγt+) — via STAT3-IL-6 → RORγt; IL-23 stabilizes phenotype. TGF-β with the inflammatory cytokines IL-6 and IL-23 induces Th17 via RORγt. Th17 cells make IL-17/IL-22 to recruit neutrophils against extracellular bacteria and fungi at barriers — and are central to psoriasis, IBD, and other autoimmunity, the target of anti-IL-17/IL-23 biologics.
  4. naive CD4+ + TGF-β + IL-2 (no IL-6) → iTreg polarization (FoxP3+) — via STAT5-IL-2 + SMAD-TGF-β → FoxP3; IL-6 redirects to Th17. The same TGF-β, but with IL-2 and without IL-6, instead induces peripheral FoxP3+ regulatory T cells (iTreg). The IL-6 switch between an inflammatory Th17 fate and a tolerogenic Treg fate from a shared TGF-β signal is a pivotal decision point — explaining how inflammation can tip the balance toward autoimmunity.
  5. Th17 ↔ iTreg → lineage plasticity (TGF-β / IL-6 balance) — via shared TGF-β; IL-6 tips the balance toward Th17. Th17 and iTreg are not fixed: they show plasticity, interconverting as the TGF-β/IL-6 balance shifts, and Th17 cells can acquire pathogenic features. This flexibility — once thought impossible for differentiated helper cells — complicates the classical lineage model and is therapeutically relevant.
  6. effector Th1/Th17 → glycolytic metabolic state (mTORC1-driven) — via distinct from Treg fatty-acid-oxidation profile (AMPK). Fate is coupled to metabolism: effector Th1/Th17 cells adopt aerobic glycolysis driven by mTORC1, whereas Tregs rely more on oxidative/fatty-acid metabolism. This divergence means mTOR inhibitors (rapamycin) preferentially spare and expand Tregs — linking immunometabolism to immunosuppressive strategy.

Known Modulators

References